Digital support to reduce self-stigma for pregnant and postpartum women with substance use disorder

A Digital Intervention to Decrease Self-Stigma Among Pregnant and Postpartum Women With Substance Use Disorder

NA · Washington University School of Medicine · NCT07211867

This project will test whether a smartphone program called Enhearten can reduce self‑stigma and help pregnant and postpartum women with substance use disorder stay in treatment and improve recovery.

Quick facts

PhaseNA
Study typeInterventional
Enrollment152 (estimated)
Ages18 Years and up
SexFemale
SponsorWashington University School of Medicine (other)
Locations1 site (St Louis, Missouri)
Trial IDNCT07211867 on ClinicalTrials.gov

What this trial studies

This multicenter individual-level randomized controlled trial will compare an augmented version of the Enhearten app (which includes a stigma-focused ecological momentary intervention, or EMI) to a waitlist control. Enhearten is designed to screen for momentary feelings of stigma and deliver just-in-time messages to counteract those vulnerabilities while promoting adherence to medications for addiction treatment. Pregnant women and new mothers up to 12 months postpartum with a history of substance use will be enrolled, randomized, and followed to measure self-stigma, treatment retention, and substance use outcomes. Feasibility and acceptability of the digital intervention will also be measured alongside efficacy outcomes.

Who should consider this trial

Good fit: Adult (≥18) pregnant women or new mothers up to 12 months postpartum who are fluent in English, have a history of non‑alcohol/non‑nicotine substance use, and have daily access to a smartphone or tablet are ideal candidates.

Not a fit: People without daily access to a smartphone or tablet, those not fluent in English, those whose substance use is limited to alcohol or nicotine only, or individuals with significant cognitive impairment are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, Enhearten could lower self-stigma, improve retention in addiction treatment, and lead to better recovery outcomes for pregnant and postpartum women.

How similar studies have performed: Some digital and EMI approaches have shown promise for supporting medication adherence and behavior change in other populations, but this specific stigma‑focused Enhearten intervention for pregnant and postpartum women with SUD is relatively novel and not yet proven.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant women and new mothers (up to 12 months postpartum)
* Adult (≥18 years of age)
* Fluent in English
* Currently owns or has ready (daily) access to a smartphone or tablet to use Enhearten.
* Self-reports a history of substance use, excluding alcohol use, nicotine/tobacco use, and drugs taken as prescribed by a physician OR a history of substance use, excluding alcohol use, nicotine/tobacco use, and drugs taken as prescribed by a physician, is identified in chart review as documented by a healthcare provider

Exclusion Criteria:

\- Significant cognitive impairment that interferes with their ability to consent and complete study tasks as self-reported or documented in medical charts by a healthcare provider

Where this trial is running

St Louis, Missouri

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Substance Use Disorder, pregnant and postpartum women, self-stigma, digital interventions, substance use disorder

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.